Centenarians Don't Age Slower — They Age Differently, With Preserved Immune Surveillance Against Senescent Cells

Centenarian studies consistently show something paradoxical: they accumulate the same types of molecular damage as people who die at 75. Similar telomere shortening. Similar mutation burden. Similar glycation. What differs is their immune system's ability to clear damaged cells.

Centenarians maintain unusually high NK cell and CD8+ T cell activity into extreme old age (Franceschi et al., 2019, Nature Reviews Immunology). Their immune systems continue to identify and eliminate senescent and pre-cancerous cells long after most people's immune surveillance has declined.

Hypothesis: The primary determinant of exceptional longevity is not slower damage accumulation but preserved immunosurveillance of damaged cells. Centenarians are natural senolytics — their immune systems do what dasatinib + quercetin does pharmacologically. Boosting immune surveillance of senescent cells will be more effective than pharmacological senolytics.

Prediction: Adoptive transfer of young NK cells (expanded ex vivo) into aged mice will clear senescent cells with efficiency matching D+Q treatment, with the added benefit of continuous surveillance rather than pulse-and-wait.